Pronecroptotic Therapy Using Ceramide Nanoliposomes Is Effective for Triple-Negative Breast Cancer Cells.

Area of Science:

• Oncology
• Nanomedicine
• Molecular Biology

Background:

• Refractory cancers, including triple-negative breast cancer (TNBC), present significant therapeutic challenges.
• Necroptosis, a regulated form of necrosis, is an emerging target for cancer therapy.
• Mixed lineage kinase domain-like protein (MLKL) is a key mediator of necroptosis.

Purpose of the Study:

• To investigate the potential of ceramide nanoliposomes (CNLs) for pronecroptotic therapy in triple-negative breast cancer (TNBC).
• To evaluate the role of MLKL expression in TNBC sensitivity to CNLs.

Main Methods:

• Analysis of MLKL mRNA expression in TNBC patient tissues and cell lines.
• Assessment of CNL efficacy in various breast cancer cell lines.
• MLKL knockdown experiments in TNBC cells (MDA-MB-231) to confirm the mechanism of cell death.

Main Results:

• MLKL expression was significantly higher in TNBC tissues and cell lines compared to non-TNBC subtypes.
• TNBC cell lines demonstrated increased susceptibility to CNL-induced cell death.
• MLKL knockdown abrogated CNL- or C6-ceramide-induced cell death in TNBC cells, confirming necroptosis mediation.

Conclusions:

• TNBC cells are particularly susceptible to CNL-induced necroptotic cell death.
• CNLs represent a promising therapeutic strategy for refractory TNBC by exploiting the necroptosis pathway.
• These findings support the development of CNL-based pronecroptotic therapies for TNBC.